

Fundamentals of the psoralen-based Helinx[trade] tech
infectious pathogens and leukocytes in platelets and pla

Seminars in Hematology

38, 4-11

DOI: 10.1053/shem.2001.29495

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatment of Acute Promyelocytic Leukemia with ATRA and As ₂ O ₃ : A Model of Molecular. Cancer Biology and Therapy, 2002, 1, 614-620.	3.4	73
2	Salmonella Sepsis Caused by a Platelet Transfusion from a Donor with a Pet Snake. New England Journal of Medicine, 2002, 347, 1075-1078.	27.0	56
3	Expression of CD117 and CD11b in Bone Marrow Can Differentiate Acute Promyelocytic Leukemia From Recovering Benign Myeloid Proliferation. American Journal of Clinical Pathology, 2002, 118, 31-37.	0.7	31
4	Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood, 2002, 100, 3141-3146.	1.4	90
5	Prevention and Treatment of Hyperuricemia in Hematological Malignancies. Clinical Lymphoma and Myeloma, 2002, 3, S26-S31.	2.1	27
6	Hyperuricemia in Patients with Cancer. American Journal of Cancer, 2002, 1, 409-422.	0.4	6
7	Clinical Q & A. Clinical Journal of Oncology Nursing, 2002, 6, 109-110.	0.6	15
8	Translocation (15;17) and trisomy 21 in the microgranular variant of acute promyelocytic leukemia. Cancer Genetics and Cytogenetics, 2002, 132, 74-76.	1.0	8
10	Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion, 2002, 42, 1302-1307.	1.6	70
11	Molecular defects in coagulation Factor VIII and their impact on Factor VIII function. Vox Sanguinis, 2002, 83, 89-96.	1.5	10
12	Inactivation of pathogens in platelet concentrates by using a two-step procedure. Vox Sanguinis, 2003, 84, 96-104.	1.5	37
13	The future use of pathogen-inactivated platelet concentrates. Vox Sanguinis, 2003, 85, 54-66.	1.5	8
14	Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sanguinis, 2003, 85, 171-182.	1.5	53
15	The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia, 2003, 9, 38-49.	2.1	165
16	Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis. Haemophilia, 2003, 9, 251-260.	2.1	41
17	The future of recombinant coagulation factors. Journal of Thrombosis and Haemostasis, 2003, 1, 922-930.	3.8	47
18	A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. Journal of Thrombosis and Haemostasis, 2003, 1, 2283-2289.	3.8	57
19	Acute arterial thrombosis in acute promyelocytic leukaemia. International Journal of Laboratory Hematology, 2003, 25, 267-270.	0.2	19

#	ARTICLE	IF	CITATIONS
20	Elitekâ„rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia, 2003, 17, 499-514.	7.2	79
22	Unique Aspects of Supportive Care Using Monoclonal Antibodies in Cancer Treatment. Supportive Cancer Therapy, 2003, 1, 38-48.	0.3	38
23	Critical issues in nephrology. Clinics in Chest Medicine, 2003, 24, 561-581.	2.1	7
24	Recombinant Urate Oxidase for Prevention of Hyperuricemia and Tumor Lysis Syndrome in Lymphoid Malignancies. Clinical Lymphoma and Myeloma, 2003, 3, 225-232.	2.1	36
25	Morphological and cytochemical characteristics of leukaemic promyelocytes. Best Practice and Research in Clinical Haematology, 2003, 16, 349-355.	1.7	15
26	A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clinica Chimica Acta, 2003, 333, 13-18.	1.1	50
27	Oncologic emergencies. Topics in Companion Animal Medicine, 2003, 18, 127-130.	0.6	4
29	Acute Tumor Lysis Syndrome Secondary to Hydroxyurea in Acute Myeloid Leukemia. Annals of Pharmacotherapy, 2003, 37, 675-678.	1.9	13
30	Progress Toward a Pathogen-Free Blood Supply. Clinical Infectious Diseases, 2003, 37, 88-95.	5.8	69
32	An Unusual Overdose of Leflunomide in a Patient with Rheumatoid Arthritis. Annals of Pharmacotherapy, 2004, 38, 1320-1321.	1.9	5
33	Tumor Lysis Syndrome Associated with Fludarabine Treatment in Chronic Lymphocytic Leukemia. Annals of Pharmacotherapy, 2004, 38, 1319-1320.	1.9	9
34	Hypocalcemia and Azotemia Associated with Zoledronic Acid and Interferon Alfa. Annals of Pharmacotherapy, 2004, 38, 418-421.	1.9	18
35	Acute Renal Failure in the Critically Ill: Impact on Morbidity and Mortality. , 2004, 144, 1-11.		50
36	Expression of CD2 in Acute Promyelocytic Leukemia Correlates With Short Form of PML-RARÎ± Transcripts and Poorer Prognosis. American Journal of Clinical Pathology, 2004, 121, 402-407.	0.7	68
37	Rasburicase Therapy in Acute Hyperuricemia and Renal Dysfunction. , 2004, 147, 115-123.		26
38	Inactivation of Plasmodium falciparum by Photodynamic Excitation of Hemeâ€Cycle Intermediates Derived from Î±-Aminolevulinic Acid. Journal of Infectious Diseases, 2004, 190, 184-191.	4.0	29
39	Recombinant Urate Oxidase (Rasburicase) in the Prophylaxis and Treatment of Tumor Lysis Syndrome. , 2004, 147, 69-79.		27
40	Pediatric Tumor Lysis Syndrome. Journal of Pharmacy Practice, 2004, 17, 447-454.	1.0	3

#	ARTICLE	IF	CITATIONS
41	A simple spectrophotometric method for the quantification of residual haemoglobin in platelet concentrates. Vox Sanguinis, 2004, 87, 264-271.	1.5	41
42	Tumour lysis syndrome: new therapeutic strategies and classification. British Journal of Haematology, 2004, 127, 3-11.	2.5	809
43	Biosynthesis of FVIII in megakaryocytic cells: improved production and biochemical characterization. British Journal of Haematology, 2004, 127, 568-575.	2.5	4
44	Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience. Haemophilia, 2004, 10, 452-458.	2.1	33
45	Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion, 2004, 44, 1496-1504.	1.6	157
46	Recovery and life span of 111 indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion, 2004, 44, 1732-1740.	1.6	90
47	Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. Cancer Genetics and Cytogenetics, 2004, 148, 176-177.	1.0	7
48	Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. Journal of Cancer Research and Clinical Oncology, 2004, 130, 623-5.	2.5	42
49	Late relapse of acute promyelocytic leukemia treated with all- trans retinoic acid and chemotherapy: report of two cases. Annals of Hematology, 2004, 83, 484-486.	1.8	18
50	Microgranular and t(11;17)/PLZF-RAR Δ variants of acute promyelocytic leukemia also present the flow cytometric pattern of CD13, CD34, and CD15 expression characteristic of PML-RAR Δ gene rearrangement. American Journal of Hematology, 2004, 76, 44-51.	4.1	19
51	Antibody binding capacity for evaluation of MDR-related proteins in acute promyelocytic leukemia: Onset versus relapse expression. Cytometry, 2004, 59B, 40-45.	1.8	7
52	In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. Journal of Clinical Apheresis, 2004, 19, 185-191.	1.3	12
54	Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. American Journal of Medicine, 2004, 116, 546-554.	1.5	273
55	Treatment of Hemophilia With Genetic Engineering. Transfusion Alternatives in Transfusion Medicine, 2004, 6, 46-54.	0.2	1
56	Practical Experience of Implementing the INTERCEPT [®] , [®] Blood System for Buffy Coat Platelets in a Blood Center. Transfusion Medicine and Hemotherapy, 2004, 31, 32-36.	1.6	8
57	Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood, 2004, 104, 1534-1541.	1.4	379
58	Rasburicase Therapy in Acute Hyperuricemic Renal Dysfunction. , 2004, 144, 158-165.		3
59	Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates. Transfusion, 2005, 45, 1464-1472.	1.6	13

#	ARTICLE	IF	CITATIONS
60	Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. <i>Transfusion</i> , 2005, 45, 1610-1620.	1.6	44
61	Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. <i>Transfusion</i> , 2005, 45, 1864-1875.	1.6	111
62	In vitro photochemical inactivation of cell-associated human T-cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen. <i>Transfusion</i> , 2005, 45, 1151-1159.	1.6	16
63	Pathogen inactivation technology: cleansing the blood supply. <i>Journal of Internal Medicine</i> , 2005, 257, 224-237.	6.0	82
64	Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek [®]), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. <i>Leukemia</i> , 2005, 19, 34-38.	7.2	162
65	Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. <i>Transfusion</i> , 2005, 45, 580-590.	1.6	158
66	Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. <i>Transfusion Medicine</i> , 2005, 15, 269-276.	1.1	35
67	Primary myeloid sarcoma of the testicle with t(15;17). <i>Cancer Genetics and Cytogenetics</i> , 2005, 157, 148-150.	1.0	18
68	Alterations in electrolyte equilibrium in patients with acute leukemia. <i>European Journal of Haematology</i> , 2005, 75, 449-460.	2.2	44
69	Bacterial Detection of Platelets: Current Problems and Possible Resolutions. <i>Transfusion Medicine Reviews</i> , 2005, 19, 259-272.	2.0	144
70	Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2005, 84, 343-346.	1.8	10
71	Gene Therapy: Molecular Engineering of Factor VIII and Factor IX. , 0, , 229-234.		0
72	Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells <i>in vitro</i> . <i>World Journal of Gastroenterology</i> , 2005, 11, 5633.	3.3	46
73	Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. <i>Platelets</i> , 2005, 16, 441-445.	2.3	16
74	Bacterial Contamination of Blood Components. <i>Clinical Microbiology Reviews</i> , 2005, 18, 195-204.	13.6	368
75	Renal Failure Associated with Cancer and Its Treatment: An Update. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 151-161.	6.1	164
76	The release of microparticles by apoptotic cells and their effects on macrophages. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2005, 10, 731-741.	4.9	127
77	Tumor Lysis Syndrome in Solid Tumors. <i>Supportive Cancer Therapy</i> , 2005, 2, 188-191.	0.3	36

#	ARTICLE	IF	CITATIONS
78	Syndrome de lyse tumorale : Épidémiologie et facteurs de risque. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2005, 14, S217-S220.	0.1	0
79	Optimizing Management of Tumor Lysis Syndrome in Adults with Hematologic Malignancies. Supportive Cancer Therapy, 2005, 2, 159-166.	0.3	16
80	Insuffisance rénale aiguë chez le malade d'oncohématologie. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2005, 14, 508-518.	0.1	2
81	Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines. Thrombosis Research, 2005, 115, 109-114.	1.7	21
83	A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leukemia and Lymphoma, 2006, 47, 877-883.	1.3	74
84	Pathogen inactivation of platelets. Transfusion Alternatives in Transfusion Medicine, 2006, 8, 121-126.	0.2	8
85	Evolving Role of Arsenic Trioxide in Acute Promyelocytic Leukemia. Clinical Leukemia, 2006, 1, 36-40.	0.2	1
86	Pathogen inactivation techniques. Best Practice and Research in Clinical Haematology, 2006, 19, 205-242.	1.7	111
87	cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology, 2006, 28, 1065.	3.3	3
88	Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea. Pediatric Blood and Cancer, 2006, 46, 439-445.	1.5	29
89	Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion, 2006, 46, 24-33.	1.6	49
90	Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion, 2006, 46, 424-433.	1.6	30
91	Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion, 2006, 46, 731-740.	1.6	59
92	Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion, 2006, 46, 800-810.	1.6	67
93	Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion, 2006, 46, 1168-1177.	1.6	142
94	Molecular response in acute promyelocytic leukemia: a direct comparison of regular and real-time RT-PCR. Leukemia, 2006, 20, 1393-1399.	7.2	10
95	Tumour Lysis Syndrome in Solid Tumours. Clinical Oncology, 2006, 18, 773-780.	1.4	114
97	Folic acid deficiency: Main etiological factor of megaloblastic anemia in Kazakhstan?. American Journal of Hematology, 2006, 81, 471-471.	4.1	3

#	ARTICLE	IF	CITATIONS
98	Morphologic heterogeneity of acute promyelocytic leukemia: Therapy-related acute promyelocytic leukemia presenting with FAB-M2 morphology. American Journal of Hematology, 2006, 81, 475-476.	4.1	1
99	Induction chemotherapy and post-remission imatinib therapy for de NovoBCR-ABL-positive AML. American Journal of Hematology, 2006, 81, 470-471.	4.1	25
100	Could the C677T mutation in the MTHFR gene be another genetic cause of arrhythmogenic right ventricular dysplasia?. American Journal of Hematology, 2006, 81, 473-474.	4.1	0
101	Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone. American Journal of Hematology, 2006, 81, 471-473.	4.1	4
102	Acute promyelocytic leukemia with secondary myelofibrosisâ€”Case report and review of the literature. American Journal of Hematology, 2006, 81, 476-477.	4.1	7
103	Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. American Journal of Hematology, 2006, 81, 474-474.	4.1	9
104	Another case of myelodysplasia with monosomy 7 following fludarabine-based chemotherapy. American Journal of Hematology, 2006, 81, 473-473.	4.1	2
105	Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrology Dialysis Transplantation, 2007, 22, 3471-3477.	0.7	71
107	Freeze-dried whole plasma: Evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers. Thrombosis Research, 2007, 120, 105-116.	1.7	42
108	Platelets and Related Products. , 2007, , 308-341.		8
109	Catalase deficiency may complicate urate oxidase (rasburicase) therapy. Free Radical Research, 2007, 41, 953-955.	3.3	20
111	Pathogen Inactivation. American Journal of Clinical Pathology, 2007, 128, 945-955.	0.7	36
113	Retinoic Acid and Arsenic Trioxide Treatment in Acute Promyelocytic Leukemia: A Model of Oncoprotein Targeted Therapy. , 0, , 371-392.		0
114	Tumor lysis syndrome in elderly. Critical Reviews in Oncology/Hematology, 2007, 64, 31-42.	4.4	25
115	Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: Long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatric Blood and Cancer, 2007, 49, 127-132.	1.5	48
116	Thrombotic thrombocytopenic purpura (TTP): Is any plasma useful to treat the TTP?. ISBT Science Series, 2007, 2, 233-239.	1.1	2
117	Defining 'full-length' recombinant factor VIII: a comparative structural analysis. Haemophilia, 2007, 13, 30-37.	2.1	41
118	ReFacto®1 and Advate®2: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia, 2007, 13, 124-130.	2.1	49

#	ARTICLE	IF	CITATIONS
119	Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods. Transfusion, 2007, 47, 1125-1133.	1.6	49
120	Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion, 2007, 48, 071005074756004-???	1.6	34
121	Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates. Transfusion, 2007, 48, 071121030748013-???	1.6	37
122	Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. European Journal of Haematology, 2007, 78, 213-219.	2.2	112
123	Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion, 2008, 48, 697-705.	1.6	47
124	Tumor lysis associated with dexamethasone use in a child with leukemia. Paediatric Anaesthesia, 2008, 18, 268-270.	1.1	20
125	Methylene blue-photoinactivated plasma <i>versus</i> quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. British Journal of Haematology, 2008, 143, 39-45.	2.5	57
127	Targeted Cancer Therapy. , 2008, , .		11
128	Tumor lysis syndrome: current perspective. Haematologica, 2008, 93, 9-13.	3.5	104
129	ACUTE RENAL FAILURE DURING ATRA TREATMENT. Pediatric Hematology and Oncology, 2008, 25, 115-118.	0.8	17
130	Rasburicase: future directions in tumor lysis management. Expert Opinion on Biological Therapy, 2008, 8, 1595-1604.	3.1	22
131	Fatigue and Easy Bruising in a 32-Year-Old Woman With a History of Heart Problems. Laboratory Medicine, 2008, 39, 211-214.	1.2	0
132	Clinical Experience with Pathogen Inactivation of Platelet Components for Transfusion Support. , 2008, , 248-263.		5
133	Bacterial Contamination of Platelet Components: Prevalence and Measures to Prevent Transfusion-Transmitted Bacterial Infection. , 2008, , 234-247.		0
134	SFCE (Soci�t� Fran�saise de Lutte contre les Cancers et Leuc�mies de l'Enfant et de l'Adolescent) Recommendations for the Management of Tumor Lysis Syndrome (TLS) With Rasburicase: An Observational Survey. Journal of Pediatric Hematology/Oncology, 2008, 30, 267-271.	0.6	17
135	S�ndrome de lise tumoral: uma revis�o abrangente da literatura. Revista Brasileira De Terapia Intensiva, 2008, 20, 278-285.	0.3	6
136	Processing and components: leucodepletion and pathogen reduction. , 0, , 239-258.		2
137	Caracter�sticas gen�ticas da leucemia promieloc�tica aguda de novo. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 454-462.	0.7	1

#	ARTICLE	IF	CITATIONS
138	Noninfectious Serious Hazards of Transfusion. <i>Anesthesia and Analgesia</i> , 2009, 108, 759-769.	2.2	360
139	Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 227-232.	4.1	8
140	Tumor lysis syndrome after transcatheter arterial infusion of cisplatin and embolization therapy for liver metastases of melanoma. <i>International Journal of Dermatology</i> , 2009, 48, 763-767.	1.0	18
141	Study of coagulation function in thawed apheresis plasma for photochemical treatment by amotosalen and UVA. <i>Vox Sanguinis</i> , 2009, 96, 213-218.	1.5	16
142	Blood-derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue. <i>ISBT Science Series</i> , 2009, 4, 136-142.	1.1	28
143	Pediatric Nephrology in the ICU. , 2009, , .		6
144	A prospective study of gout and cancer. <i>European Journal of Cancer Prevention</i> , 2009, 18, 127-132.	1.3	79
145	A case of fatal overwhelming microgranular variant (M3v) of acute promyelocytic leukemia with extensive extramedullary involvement. <i>International Journal of Hematology</i> , 2010, 91, 551-552.	1.6	0
146	Childhood rhabdomyosarcoma metastatic to bone marrow presenting with disseminated intravascular coagulation and acute tumour lysis syndrome: review of the literature apropos of two cases. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 399-407.	3.3	25
147	Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody. <i>Cancer</i> , 2010, 116, 369-376.	4.1	45
148	PML/RAR- α fusion transcript and polyploidy in acute promyelocytic leukemia without t(15;17). <i>Leukemia Research</i> , 2010, 34, e261-e263.	0.8	4
149	An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. <i>Transfusion</i> , 2010, 50, 1210-1219.	1.6	46
150	Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 286-293.	3.8	20
151	Purification and characterization of a new recombinant factor VIII (N8). <i>Haemophilia</i> , 2010, 16, 349-359.	2.1	106
152	INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis. <i>Vox Sanguinis</i> , 2010, 98, 47-55.	1.5	28
153	Acute Promyelocytic Leukemia at Time of Relapse Commonly Demonstrates Cytogenetic Evidence of Clonal Evolution and Variability in Blast Immunophenotypic Features. <i>American Journal of Clinical Pathology</i> , 2010, 133, 484-490.	0.7	18
154	Approaches for Administering Chemotherapy in the Intensive Care Unit. <i>Current Drug Safety</i> , 2010, 5, 22-32.	0.6	8
155	Bacterial Contamination of Platelet Concentrates: Perspectives for the Future: Table 1. <i>Laboratory Medicine</i> , 2010, 41, 301-305.	1.2	7

#	ARTICLE	IF	CITATIONS
156	Umbilical Cord Blood Transplantation for Thalassemia Major. Hematology/Oncology Clinics of North America, 2010, 24, 1165-1177.	2.2	10
157	Life-threatening hyperkalemia during radiofrequency ablation of hepatocellular carcinoma. Journal of Clinical Anesthesia, 2010, 22, 473-476.	1.6	3
158	Fluid and Electrolytes in Pediatrics. , 2010, , .		3
159	Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leukemia and Lymphoma, 2010, 51, 221-227.	1.3	87
160	Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro. Lung Cancer, 2011, 74, 178-187.	2.0	15
161	Acute Lymphocytic Leukemia “ Clinical Features and Making the Diagnosis. , 2011, , 9-24.		2
162	Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™. Transfusion Medicine and Hemotherapy, 2011, 38, 19-31.	1.6	149
163	The Relationship between Serum Uric Acid and Spirometric Values in Participants in a Health Check: The Takahata Study. International Journal of Medical Sciences, 2011, 8, 470-478.	2.5	52
164	Management of Pediatric Tumor Lysis Syndrome. Sudanese Journal of Ophthalmology, 2011, 4, 147-54.	0.0	5
165	The role of the annexin A2 heterotetramer in vascular fibrinolysis. Blood, 2011, 118, 4789-4797.	1.4	105
166	The clinical management of tumour lysis syndrome in haematological malignancies. British Journal of Haematology, 2011, 154, 3-13.	2.5	50
167	The extent of amotosalen photodegradation during photochemical treatment of platelet components correlates with the level of pathogen inactivation. Transfusion, 2011, 51, 52-61.	1.6	12
168	Metabolic Emergencies in the Child With Acute Leukemia. Clinical Pediatric Emergency Medicine, 2011, 12, 191-201.	0.4	1
170	Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients. Medical Oncology, 2011, 28, 513-521.	2.5	23
171	Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report. Journal of Medical Case Reports, 2011, 5, 407.	0.8	6
172	Tumor lysis syndrome developing intraoperatively. Journal of Anaesthesiology Clinical Pharmacology, 2011, 27, 561.	0.7	6
173	Using Limes and Synthetic Psoralens to Enhance Solar Disinfection of Water (SODIS): A Laboratory Evaluation with Norovirus, Escherichia coli, and MS2. American Journal of Tropical Medicine and Hygiene, 2012, 86, 566-572.	1.4	40
174	Tumor Lysis Syndrome: A Systematic Review of Case Series and Case Reports. Postgraduate Medicine, 2012, 124, 92-101.	2.0	36

#	ARTICLE	IF	CITATIONS
175	Onco-Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1730-1739.	4.5	110
176	Heparinâ€integrin interaction in endothelial cells: Downstream signaling and heparan sulfate expression. Journal of Cellular Physiology, 2012, 227, 2740-2749.	4.1	13
177	Lysis syndrome during therapy of visceral leishmaniasis. Infection, 2012, 40, 121-123.	4.7	7
178	Metaâ€analysis of the studies of bleeding complications of platelets pathogenâ€reduced with the Intercept system. Vox Sanguinis, 2012, 102, 302-316.	1.5	43
179	Tumour lysis syndrome and acute kidney injury in highâ€risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en <scp>R</scp>Ã©animation Respiratoire et <scp>O</scp>ncoâ€<scp>H</scp>Ã©matologique. British Journal of Haematology, 2013, 162, 489-497.	2.5	90
180	Burkittâ€™s Lymphoma. , 2013, , .		2
181	t(15;17)(q24.1;q21.2)/PML-RARA in blast phase of chronic myelogenous leukemia: a rare form of clonal evolution. Journal of Hematopathology, 2013, 6, 187-193.	0.4	6
182	Update on the use of pathogenâ€reduced human plasma and platelet concentrates. British Journal of Haematology, 2013, 162, 442-454.	2.5	74
183	Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature <scp>B</scp>â€<scp>NHL</scp>: a <scp>C</scp>hildren's <scp>O</scp>ncology <scp>G</scp>roup <scp>R</scp>eport. British Journal of Haematology, 2013, 163, 365-372.	2.5	49
184	A patientâ€oriented riskâ€benefit analysis of pathogenâ€inactivated blood components: application to apheresis platelets in the United States. Transfusion, 2013, 53, 1603-1618.	1.6	38
185	Biochemical and functional characterization of a recombinant monomeric factorâ€VIIIâ€Fc fusion protein. Journal of Thrombosis and Haemostasis, 2013, 11, 132-141.	3.8	116
186	Acute Promyelocytic Leukemia. , 2013, , 403-453.		0
187	Therapeutic Approaches to Burkittâ€™s Lymphoma. , 2013, , 251-268.		1
188	A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy. Molecular Therapy, 2013, 21, 1076-1086.	8.2	17
189	Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thrombosis Research, 2013, 131, 78-88.	1.7	108
190	Tumour lysis syndrome; new approaches at diagnose, follow up and treatment. Turk Pediatri Arsivi, 2013, 48, 188-194.	0.9	0
191	Immunostaining for Rapid Diagnosis of Acute Promyelocytic Leukemia with the Tetramethylrhodamine-5-Isothiocyanateâ€Conjugated Antiâ€Promyelocytic Leukemia Monoclonal Antibody PG-M3. Archives of Pathology and Laboratory Medicine, 2013, 137, 1669-1673.	2.5	7
192	Photochemical Inactivation of Chikungunya Virus in Human Apheresis Platelet Components by Amotosalen and UVA Light. American Journal of Tropical Medicine and Hygiene, 2013, 88, 1163-1169.	1.4	25

#	ARTICLE	IF	CITATIONS
193	Perioperative management of hemostasis. , 0, , 223-233.		0
194	A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity. PLoS ONE, 2014, 9, e113600.	2.5	12
195	Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: An Indian experience. Indian Journal of Cancer, 2014, 51, 180.	0.2	2
196	The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Reviews, 2014, 28, 235-241.	5.7	106
197	Turoctocog alfa (NovoEight [®]) â€” from design to clinical proof of concept. European Journal of Haematology, 2014, 93, 369-376.	2.2	28
198	Tumor Lysis Syndrome. , 2014, , 39-64.		5
199	Comparative study of the efficacy of Wright-Giemsa stain and Liu's stain in the detection of Auer rods in acute promyelocytic leukemia. Acta Histochemica, 2014, 116, 1113-1116.	1.8	10
200	Microgranular variant of acute promyelocytic leukemia with der(17) ins(17;15): A case report and review of the literature. Experimental and Therapeutic Medicine, 2015, 10, 1009-1012.	1.8	2
201	Treatment of platelets with riboflavin and ultraviolet light mediates complement activation and suppresses monocyte interleukin-12 production in whole blood. Vox Sanguinis, 2015, 109, 327-335.	1.5	7
202	Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia. Brazilian Journal of Medical and Biological Research, 2015, 48, 178-185.	1.5	2
203	Central nervous system haemorrhage causing early death in acute promyelocytic leukaemia. Central-European Journal of Immunology, 2015, 4, 486-488.	1.2	3
204	Prediction of Drug Indications Based on Chemical Interactions and Chemical Similarities. BioMed Research International, 2015, 2015, 1-14.	1.9	3
205	Increased Risk of Cancer in relation to Gout: A Review of Three Prospective Cohort Studies with 50,358 Subjects. Mediators of Inflammation, 2015, 2015, 1-6.	3.0	37
206	Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects. Transfusion and Apheresis Science, 2015, 52, 240-244.	1.0	21
207	Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets, 2015, 26, 154-163.	2.3	60
208	Hemostatic properties and protein expression profile of therapeutic apheresis plasma treated with amotosalen and ultraviolet A for pathogen inactivation. Transfusion, 2016, 56, 2239-2247.	1.6	5
209	Neonatal Platelet Transfusions and Future Areas of Research. Transfusion Medicine Reviews, 2016, 30, 183-188.	2.0	36
210	Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42-q43;q11.2-12): a case report. Journal of Medical Case Reports, 2016, 10, 203.	0.8	8

#	ARTICLE	IF	CITATIONS
211	Past, present and forecast of transfusion medicine: What has changed and what is expected to change?. Presse Medicale, 2016, 45, e253-e272.	1.9	2
212	Effects of riboflavin and amotosalen photoactivation systems for pathogen inactivation of fresh-frozen plasma on fibrin clot structure. Transfusion, 2016, 56, 41-48.	1.6	9
213	Assessment of nucleic acid modification induced by amotosalen and ultraviolet A light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA. Transfusion, 2016, 56, 410-420.	1.6	19
214	Technical comparison of four different extracorporeal photopheresis systems. Transfusion, 2016, 56, 2510-2519.	1.6	29
215	Challenges and opportunities for monoclonal antibody therapy in veterinary oncology. Veterinary Journal, 2016, 218, 40-50.	1.7	13
216	Characterization of Therapeutic Proteins. Topics in Medicinal Chemistry, 2016, , 69-121.	0.8	4
217	Elevated uric acid and adenosine triphosphate concentrations in bronchoalveolar lavage fluid of eosinophilic pneumonia. Allergology International, 2017, 66, S27-S34.	3.3	9
218	Cancer cells induce interleukin-22 production from memory CD4 ⁺ T cells via interleukin-1 to promote tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12994-12999.	7.1	115
219	Annexin A2-S100A10 heterotetramer is upregulated by PML/RAR α fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia. Frontiers of Medicine, 2017, 11, 410-422.	3.4	28
220	Neonatal Transfusion Practices. , 2017, , .		2
222	Adverse Reactions. , 2017, , 81-102.		0
223	CAR T-cells for cancer therapy. Biotechnology and Genetic Engineering Reviews, 2017, 33, 190-226.	6.2	28
224	Tumor Lysis Syndrome in Patients with Hematological Malignancies. Journal of Oncology, 2017, 2017, 1-9.	1.3	72
225	Killed but metabolically active Pseudomonas aeruginosa -based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections. Vaccine, 2018, 36, 1893-1900.	3.8	17
226	Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future. Archives of Pathology and Laboratory Medicine, 2018, 142, 662-667.	2.5	28
228	The platelets TM perspective to pathogen reduction technologies. Platelets, 2018, 29, 140-147.	2.3	16
229	Current Risks of Transfusion. , 2018, , 279-303.		0
232	New Concepts in Transfusion Medicine. , 2018, , 177-184.		1

#	ARTICLE	IF	CITATIONS
233	Risk-Based Decision Making in Transfusion Medicine. , 2019, , 151-161.		0
234	Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions. Transfusion, 2019, 59, 3727-3735.	1.6	3
235	The diagnostic use of ADVIA 2120i Siemens and an "APL criteria" can help to reduce the rate of early death in the APL. International Journal of Laboratory Hematology, 2019, 41, 124-132.	1.3	5
236	Damage Control Resuscitation. , 2020, , .		8
237	Metabolomics study of platelet concentrates photochemically treated with amotosalen and UVA light for pathogen inactivation. Transfusion, 2020, 60, 367-377.	1.6	5
238	Does Offline Beat Inline Treatment: Investigation into Extracorporeal Photopheresis. Transfusion Medicine and Hemotherapy, 2020, 47, 198-204.	1.6	7
239	Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. Annals of Hematology, 2020, 99, 2787-2800.	1.8	15
240	Activity of transgene-produced B-domain"deleted factor VIII in human plasma following AAV5 gene therapy. Blood, 2020, 136, 2524-2534.	1.4	48
241	Complete Inactivation of Blood Borne Pathogen Trypanosoma cruzi in Stored Human Platelet Concentrates and Plasma Treated With 405 nm Violet-Blue Light. Frontiers in Medicine, 2020, 7, 617373.	2.6	12
242	Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates. Vaccine, 2020, 38, 3313-3320.	3.8	16
243	A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. Cancer Medicine, 2020, 9, 2603-2610.	2.8	14
244	Investigation of fibrinogen in early bleeding of patients with newly diagnosed acute promyelocytic leukemia. Platelets, 2021, 32, 677-683.	2.3	8
245	Dried Plasma. , 2020, , 145-162.		5
246	Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet mRNA Transcriptome Triggered by Pathogen Reduction Systems. PLoS ONE, 2015, 10, e0133070.	2.5	38